- Ovarian cancer diagnosis and treatment
- Epigenetics and DNA Methylation
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Zebrafish Biomedical Research Applications
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- BRCA gene mutations in cancer
- MicroRNA in disease regulation
- Cellular Mechanics and Interactions
- Cell death mechanisms and regulation
- Bone Tissue Engineering Materials
- Cancer Mechanisms and Therapy
- 3D Printing in Biomedical Research
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
Ghent University
2020-2024
Ghent University Hospital
2020-2024
Cancer Research Institute Ghent
2020-2024
Abstract Ovarian cancer is the most lethal gynecologic malignancy, mainly due to late-stage diagnosis, frequent recurrences, and eventually therapy resistance. To identify potentially actionable genetic variants, sequencing data of 351 Belgian ovarian patients were retrospectively captured from electronic health records. The cohort included 286 (81%) with high-grade serous cancer, 17 (5%) low-grade 48 (14%) other histotypes. Firstly, an overview prevalence spectrum BRCA1/2 variants...
Ovarian cancer (OC) is an umbrella term for cancerous malignancies affecting the ovaries, yet treatment options all subtypes are predominantly derived from high-grade serous ovarian cancer, largest subgroup. The concept of "functional precision medicine" involves gaining personalized insights on therapy choice, based direct exposure patient tissues to drugs. This especially holds promise rare like low-grade (LGSOC). study aims establish in vivo model LGSOC using zebrafish embryos, comparing...
Abstract Background Long-term drug evaluation heavily relies upon rodent models. Drug discovery methods to reduce animal models in oncology may include three-dimensional (3D) cellular systems that take into account tumor microenvironment (TME) cell types and biomechanical properties. Methods In this study we reconstructed a 3D using an elastic polymer (acrylate-endcapped urethane-based poly(ethylene glycol) (AUPPEG)) with clinical relevant stiffness. Single suspensions from low-grade serous...
Ovarian cancer (OC) is an umbrella term for cancerous malignancies affecting the ovaries, yet treatment options all subtypes are predominantly derived from high-grade serous ovarian cancer, largest subgroup. The concept of "functional precision medicine" involves gaining personalized insights on therapy choice, based direct exposure patient tissues to drugs. This especially holds promise rare like low-grade (LGSOC). study aims establish in vivo model LGSOC using zebrafish...
Abstract Pancreatic cancer has a 5-year survival rate of merely 12%. The high late-stage diagnoses underscores the need for reliable biomarkers early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as promising biomarker, yet their remains challenging due to rarity phenotypic diversity. This study evaluates Parsortix® system, microfluidic device designed enrich CTCs based on size deformability, using pancreatic cell lines. As increasing evidence indicates that...
Abstract Ovarian cancer is characterized by poor prognosis and high relapse rate, unfortunately accompanied with resistance to previously used therapy. Currently, defined the time between treatment progression of disease. A better model test make patient-derived xenografts (PDX). We propose here development a PDX platform in zebrafish. This allows testing both possible other strategies. The fast readout less than 15 days limited amount material required (few 100s cells) allow implementation...
Abstract Ovarian cancer is the most lethal gynecologic malignancy, mainly due to late-stage diagnosis, frequent recurrences, and eventually therapy resistance. To identify potentially actionable genetic variants, sequencing data of 351 Belgian ovarian patients were retrospectively captured from electronic health records. The cohort included 286 (81%) with high-grade serous cancer, 17 (5%) low-grade 48 (14%) other histotypes. Firstly, an overview prevalence spectrum BRCA1/2 variants...